Finasteride 5 mg Tablets, Non-fasting

Summary

The objective of this study is to compare the relative bioavailability of finasteride 5 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of PROSCAR® 5 mg tablets (Merck) in healthy, adult, non-smoking, male subjects under non-fasting conditions.

Timeline

Start

2002-06

Primary completion

2002-07

Completion

2002-07

Outcome

Met primary endpoint

registry Geometric Test/Ref Ratio x 100 101 (90% CI 94.2 to 109) NCT00835796 ↗

registry Geometric Test/Ref Ratio x 100 98.7 (90% CI 94.0 to 104) NCT00835796 ↗

registry Geometric Test/Ref Ratio x 100 98.8 (90% CI 94.5 to 103) NCT00835796 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Finasteride	Small molecule	5 mg	—

Indications

No indication recorded.